Alivira Animal Health

What Alivira Animal Health does

Alivira Animal Health Limited is an India-headquartered, globally integrated veterinary pharmaceuticals company formed via the 2024 merger of SeQuent Scientific and Viyash Life Sciences, operating as a wholly-owned subsidiary of Carlyle-backed Viyash Scientific. The company manufactures Active Pharmaceutical Ingredients (APIs) and Finished Dosage Formulations (FDFs) for animal health, spanning therapeutic categories including macrolides, quinolones, lincosamides, NSAIDs, beta-lactams, hormones, anti-parasitics, and nutritional supplements, across 12 dosage forms. It operates five manufacturing facilities in India (Ambernath, Vizag, Mahad with 270 KL reactor capacity), Brazil, Turkey (EUGMP), Spain (EUGMP), and Italy, complemented by sales operations across Belgium, the Netherlands, Sweden, Mexico, and the USA, with WHO Prequalification for Albendazole API, Brazil GMP, and Turkish GMP approvals.

The company serves two primary end markets: food-producing animals (livestock) via anti-infectives, anti-parasitics, reproductive health products, and nutritional supplements, and companion animals (pets) via pharmaceuticals, nutritional complements, and rapid diagnostic tests, with growing emphasis on dermatology and ophthalmology through the BioForLife acquisition. Its go-to-market relies on direct sales through wholly-owned subsidiaries and distribution partnerships, exemplified by the Boehringer Ingelheim India collaboration for companion animal products. Alivira monetizes through B2B hardware/API and formulation sales and analytical services, with quote-based pricing not publicly disclosed.

Alivira's revenue model is anchored in manufacturing scale (5 plants, 270 KL reactor capacity, 12 dosage forms), regulatory approvals across multiple jurisdictions, and a distribution network spanning 100+ countries. Strategic activity is driven by Carlyle's ownership thesis, with multiple acquisitions (Topkim, Interchange, Bremer Pharma, BioForLife, Therapet), the SeQuent-Viyash merger, and channel partnerships supporting expansion into Europe, LATAM, the Middle East, and the Indian companion animal market. The company positions itself as India's largest and first globally integrated animal health company, though specific revenue figures are not publicly disclosed.

Name

Alivira Animal Health

Legal name

Alivira Animal Health Limited

Website

https://alivira.co

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Alivira Animal Health is India's largest integrated veterinary pharmaceuticals company manufacturing APIs and finished dosage formulations for livestock and companion animals across 100+ countries, operating 5 manufacturing sites and backed by Carlyle through parent Viyash Scientific.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Other Animal Food Manufacturing (311119)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB)

akta.pro secondary industries

Veterinary Pharmaceutical Wholesalers & Distributors (HLAMAIAA), Medicated Feed Additives & Premixes (Veterinary Pharmaceuticals) (HLAMAEAN)

Keywords

• Veterinary pharmaceuticals
• Animal health formulations
• Active pharmaceutical ingredients
• Finished dosage formulations
• Veterinary API manufacturing

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Veterinary API Manufacturing & Sales: Alivira manufactures and sells Active Pharmaceutical Ingredients (APIs) for animal health to pharmaceutical companies and formulators globally. API manufacturing spans multiple facilities in India (Ambernath, Vizag, Mahad) with reactor capacity of 270 KL across seven reactors.
2. Veterinary Finished Dosage Formulations (FDF): Manufacture and sale of finished dosage formulations including injectables, powders, oral solutions, tablets, chewable tablets, pour-on, spot-on, intramammaries, aerosols, and premixes across global markets in 100+ countries.
3. Analytical Services: Providing quality analytical testing and services for API and formulation products.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Alivira Animal Health manufactures and supplies Active Pharmaceutical Ingredients (APIs) and Finished Dosage Formulations (FDF) for veterinary and animal health applications, producing steriles, injectables, powders, oral solutions, tablets, premixes, and boluses. It complements its manufacturing with in-house Analytical Services and dedicated R&D centers, serving veterinary pharmaceutical companies, integrators, and distributors in more than 100 countries through its own subsidiaries and partners.

Product overview

Alivira Animal Health is India's largest integrated animal health company specializing in manufacturing of Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF) with presence in 100+ countries. The product portfolio includes Vet Formulation products (Resfur RTU, Calject, M-ject, EstrUp Bolus, WORMITAL), APIs for various therapeutic applications, and Analytical Services. The company operates manufacturing facilities across India (Ambernath, Vizag, Mahad), Brazil (Campinas/SP & Uberlândia/MG), Turkey (Ankara), Spain (Barcelona), Belgium (Leuven), Mexico, USA, Sweden (Uppsala), Italy (Ferrara), and Netherlands (Amsterdam).

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Over 80% of veterinary clinics in Italy served
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• BioForLife Italia S.r.l.coreStrategic or Co-development Partner · 8 June 2026Viyash Scientific, through its wholly owned subsidiary Alivira Animal Health, signed a binding agreement to acquire 100% stake in BioForLife Italia S.r.l., a Milan-based pet care company for approximately Rs 188 crore. BioForLife specializes in pet care products including nutritional complements, pharmaceuticals, and rapid diagnostic tests, with growing positions in dermatology and ophthalmology segments. The acquisition provides an established platform in Italy's companion animal care market, reaching over 80% of veterinary clinics. The deal is expected to close in Q2 FY2026-27 and enables expansion across Europe, Middle East, Asia, and LATAM markets.
• Boehringer Ingelheim IndiacoreGTM or Marketing Partner · 22 January 2026Boehringer Ingelheim India partnered with Alivira Animal Health (wholly owned subsidiary of Viyash Scientific) to distribute and promote companion animal products across India. The partnership aims to capitalize on the growing Indian pet healthcare market driven by increased pet ownership, rising awareness of preventive care, and emphasis on animal well-being. Alivira's extensive geographical reach expands Boehringer Ingelheim's sales capability across urban and rural India.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Virbac: France-based global animal health company specializing in veterinary pharmaceuticals, vaccines, and diagnostics across companion and food-producing animals. Virbac competes directly with Alivira in finished dosage formulations and shares a similar mid-sized global animal health profile with multi-regional manufacturing.
• Vetoquinol: Independent French animal health company focused on veterinary pharmaceuticals for companion and production animals. Vetoquinol is highly comparable to Alivira in business model, multi-region manufacturing footprint, and product categories (anti-infectives, anti-parasitics, reproductive health).
• Phibro Animal Health: US-based global animal health and nutrition company specializing in APIs, medicated feed additives, and vaccines for livestock. Phibro is highly comparable to Alivira's API manufacturing and feed additive premix business, particularly in antimicrobial and nutritional product categories.
• Indian Immunologicals: India-based veterinary and human biologicals manufacturer (subsidiary of National Dairy Development Board), focused on animal vaccines and health products. Indian Immunologicals is a direct Indian market peer to Alivira in the livestock and companion animal health space.
• Dechra Pharmaceuticals: UK-based veterinary pharmaceutical company focused on companion animal and equine therapeutics (acquired by EQT). Dechra's specialty pharma model and emphasis on companion animal endocrinology, dermatology, and ophthalmology directly overlaps with Alivira's BioForLife-acquired focus areas.
• Hester Biosciences: India-based veterinary biological and pharmaceutical company specializing in vaccines and animal health products. Hester is a direct domestic peer to Alivira in the Indian animal health market, with overlap in poultry and livestock vaccines and therapeutics.

Broad incumbents

• Elanco Animal Health: Major global animal health company with broad portfolio in companion animal therapeutics, livestock health, and APIs. Elanco competes with Alivira across multiple therapeutic categories and represents a likely strategic acquirer or competitive threat in the global veterinary API and formulation space.
• Zoetis: World's largest pure-play animal health company offering APIs, finished formulations, vaccines, diagnostics, and devices across companion and livestock animals. Zoetis is a direct comparator in veterinary pharmaceutical manufacturing and global distribution, though at significantly larger scale and broader portfolio depth than Alivira.
• MSD Animal Health (Merck): Animal health division of Merck, one of the largest global players in veterinary pharmaceuticals, vaccines, and APIs. MSD is a key competitor in veterinary API manufacturing and finished formulation segments, and a dominant force in regulated markets where Alivira is expanding.

Peers

• Boehringer Ingelheim Animal Health:

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/aliviraanimalhealth
• LinkedInlinkedin.com/company/alivira-animal-health
• Instagraminstagram.com/alivirapet?igsh=d3dmNHY4azFqZmx0%20

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries10 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alivira Animal Health